Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria

Objective: To assess the pharmacokinetics and relative bioavailability/bioe quivalence of three commercial tablet formulations of mefloquine, i.e. Lari am (reference formulation), Mephaquin 100 Lactab and Eloquin-250, when give n sequentially after dihydro-artemisinin in Thai patients with acute uncomp licated falciparum malaria. Methods: Twenty-nine Thai patients with acute uncomplicated falciparum mala ria were randomised to receive an initial dose of 300 mg dihydroartemisinin , followed by 1250 mg mefloquine (at 24 h and 30 h after dihydroartemisinin ) given as either Lariam (n=10 cases), Mephaquin (n=9 cases) or Eloquin-250 (n=10 cases). Serial blood samples were obtained up to day 42 after treatm ent with mefloquine. Mefloquine concentrations were determined in whole blo od by means of ultraviolet high-performance liquid chromography. The pharma cokinetic parameters of mefloquine were estimated using non-compartmental a nd comparmental analysis. Results: The three combination regimens were well tolerated. However, nine patients (four and five cases in regimen containing Mephaquin 100 Lactab an d Eloquin-250, respectively) had reappearance of parasitaemia during the fo llow-up period. Mefloquine from the three formulations showed significantly different pharmacokinetic and bioavailability metrics. Significantly lower peak plasma concentrations (C-max) and areas under the plasma concentratio n-tome curve (AUC; AUC(0-48h), AUC(0-7days), and total AUC) were observed w ith Mephaquin 100 Lactab than with the other two formulations. Mean values for relative bioavailability of the test to standard products were 49.1% (M ephaquin 100 Lactab) and 72.4% (Eloquine-250). Based on the criteria set, t he bioavailability of the two tests products (Mephaquin 100 Lactab and Eloq uine-250) was considered non-equivalent to the reference product with respe ct to the rate (t(max), C-max) and extent (AUC(0-48)h, AUC(0-7days), total AUC) of mefloquine absorption.